LISTING OF CLAIMS

Claims 1-12 (Previously canceled):

Claim 13. (Currently amended): A compound of the formula (I):



(I),

wherein:

X denotes an oxygen or sulphur atom;

R_1 denotes a C_{2-3}-alkenyl, C_{2-3}-alkynyl, aryl, aryl-C_{1-3}-alkyl, heteroaryl, heteroaryl-C_{1-3}-alkyl, trifluoromethyl or cyano group,

a hydroxy, C_{1-3}-alkoxy, hydroxy-C_{1-3}-alkyl, C_{1-3}-alkoxy-C_{1-3}-alkyl, aryloxy or heteroaryloxy group,

a mercapto, C_{1-3}-alkylsulphenyl, phenylsulphenyl, benzylsulphenyl, C_{1-3}-alkylsulphinyl, phenylsulphinyl, benzylsulphinyl, C_{1-3}-alkylsulphonyl, phenylsulphonyl, benzylsulphonyl, sulpho, C_{1-3}-alkoxysulphonyl, phenoxysulphonyl or benzyloxysulphonyl group,

an amino, C_{1-3}-alkylamino, di-(C_{1-3}-alkyl)-amino, hydroxycarbonyl-C_{1-3}-alkylamino, N-(C_{1-3}-alkyl)-hydroxycarbonyl-C_{1-3}-alkylamino, C_{1-3}-alkoxycarbonyl-C_{1-3}-alkylamino, N-(C_{1-3}-alkyl)-C_{1-3}-alkoxycarbonyl-C_{1-3}-alkylamino, phenylamino, N-phenyl-C_{1-3}-alkylamino,

N,N-diphenylamino, benzylamino, N-benzyl-C_{1-3}-alkylamino, N,N-dibenzylamino, C_{1-3}-alkylcarbonylamino, benzoylamino, benzylcarbonylamino group or an N-(C_{1-3}-alkyl)-C_{1-3}-alkylcarbonylamino group wherein the two alkyl groups are optionally replaced by a C_{2-5}-n-alkylene bridge or wherein one or both alkyl groups are optionally replaced by a phenyl or benzyl group,

a C_{1-3}-alkylsulphonylamino, phenylsulphonylamino or benzylsulphonylamino group or an N-(C_{1-3}-alkyl)-C_{1-3}-alkylsulphonylamino group wherein the two alkyl groups are optionally replaced by a C_{2-5}-n-alkylene bridge or wherein one or both alkyl groups are optionally replaced by a phenyl or benzyl group,

an aminosulphonyl, C_{1-3}-alkylaminosulphonyl, phenylaminosulphonyl, benzylaminosulphonyl, di-(C_{1-3}-alkyl)-aminosulphonyl, N,N-diphenyl-aminosulphonyl or N,N-dibenzyl-aminosulphonyl group,

a phosphono, (C_{1-3}-alkoxy)PO(H), (C_{1-3}-alkoxy)PO(C_{1-3}-alkyl), (C_{1-3}-alkoxy)PO(OH), di-(C_{1-3}-alkoxy)-PO or (C_{2-4}-n-alkylenedioxy)-PO group,

a ureido group optionally mono-, di- or trisubstituted by C_{1-3}-alkyl groups,

a 4- to 7-membered cycloalkyleneimino or cycloalkyleneiminosulphonyl group, wherein in each case the methylene group in the 4 position of a 6- or 7-membered cycloalkyleneimino group is optionally replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, -NH or -N(C_{1-3}-alkyl) group;

R_2 denotes a hydrogen, fluorine, chlorine, bromine or iodine atom,

a C_{1-6}-alkyl or trifluoromethyl group,

a hydroxy, C_{1-3}-alkoxy, mercapto, C_{1-3}-alkylsulphenyl, C_{1-3}-alkylsulphinyl, C_{1-3}-alkylsulphonyl, sulpho, C_{1-3}-alkoxysulphonyl, aminosulphonyl, C_{1-3}-alkylaminosulphonyl or di-(C_{1-3}-alkyl)-aminosulphonyl group,

a nitro, amino, C_{1-3}-alkylamino or di-(C_{1-3}-alkyl)-amino group,

a C_{1-3}-alkylcarbonyl, cyano, carboxy, C_{1-3}-alkoxycarbonyl, aminocarbonyl, C_{1-3}-alkylaminocarbonyl or di-(C_{1-3}-alkyl)-aminocarbonyl group,

a phosphono, (C_{1-3}-alkoxy)PO(H), (C_{1-3}-alkoxy)PO(C_{1-3}-alkyl), (C_{1-3}-alkoxy)PO(OH) or di-(C_{1-3}-alkoxy)-PO group,

a 4- to 7-membered cycloalkyleneimino, cycloalkyleneiminocarbonyl or cycloalkyleneiminosulphonyl group, wherein in each case the methylene group in the 4 position of a 6- or 7-membered cycloalkyleneimino group is optionally replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, -NH or -N(C_{1-3}-alkyl) group, or

R_1 and R_2 together denote a methylenedioxy, ethylenedioxy, n-propylene, n-butylene or 1,4-butadienylene group;

R_3 denotes ~~a hydrogen atom, denotes a C_{1-6}-alkyl, C_{3-7}-cycloalkyl, trifluoromethyl or heteroaryl group,~~

a phenyl ~~or naphthyl group optionally mono- or disubstituted by a fluorine, chlorine, bromine or iodine atom, by a trifluoromethyl, C_{1-3}-alkyl or C_{1-3}-alkoxy group, wherein if the phenyl or naphthyl group are disubstituted the substituents are identical or different and are optionally substituted by:~~

~~a hydroxy, hydroxy-C_{1-3}-alkyl or C_{1-3}-alkoxy-C_{1-3}-alkyl group,~~

~~by a cyano, cyano-C_{1-3}-alkyl, cyano-C_{2-3}-alkenyl, cyano-C_{2-3}-alkynyl, carboxy, carboxy-C_{1-3}-alkyl, carboxy-C_{2-3}-alkenyl, carboxy-C_{2-3}-alkynyl, C_{1-3}-alkoxycarbonyl, C_{1-3}-alkoxycarbonyl-C_{1-3}-alkyl, C_{1-3}-alkoxycarbonyl-C_{2-3}-alkenyl or C_{1-3}-alkoxycarbonyl-C_{2-3}-alkynyl group,~~

~~by a C_{1-3}-alkylcarbonyl, C_{1-3}-alkylcarbonyl-C_{1-3}-alkyl, C_{1-3}-alkylcarbonyl-C_{2-3}-alkenyl or C_{1-3}-alkylcarbonyl-C_{2-3}-alkynyl group,~~

~~by an aminocarbonyl, aminocarbonyl-C_{1-3}-alkyl, aminocarbonyl-C_{2-3}-alkenyl, aminocarbonyl-C_{2-3}-alkynyl, C_{1-3}-alkylaminocarbonyl, C_{1-3}-alkylaminocarbonyl-C_{1-3}-alkyl, C_{1-3}-alkylaminocarbonyl-C_{2-3}-alkenyl, C_{1-3}-alkylaminocarbonyl-C_{2-3}-alkynyl, di-(C_{1-3}-alkyl)-aminocarbonyl, di-(C_{1-3}-alkyl)-aminocarbonyl-C_{1-3}-alkyl, di-(C_{1-3}-alkyl)-aminocarbonyl-C_{2-3}-alkenyl or di-(C_{1-3}-alkyl)-aminocarbonyl-C_{2-3}-alkynyl group,~~

~~by a nitro, nitro-C_{1-3}-alkyl, nitro-C_{2-3}-alkenyl or nitro-C_{2-3}-alkynyl group,~~

~~by an amino, C_{1-3}-alkylamino, di-(C_{1-3}-alkyl)-amino, amino-C_{1-3}-alkyl, C_{1-3}-alkylamino-C_{1-3}-alkyl or di-(C_{1-3}-alkyl)-amino-C_{1-3}-alkyl group,~~

~~by a C_{1-3}-alkylcarbonylamino, C_{1-3}-alkylcarbonylamino-C_{1-3}-alkyl, N-(C_{1-3}-alkyl)-C_{1-3}-alkylcarbonylamino, N-(C_{1-3}-alkyl)-C_{1-3}-alkylcarbonylamino-C_{1-3}-alkyl, C_{1-3}-alkylsulphonylamino, C_{1-3}-alkylsulphonylamino-C_{1-3}-alkyl, N-(C_{1-3}-alkyl)-C_{1-3}-alkylsulphonylamino or N-(C_{1-3}-alkyl)-C_{1-3}-alkylsulphonylamino-C_{1-3}-alkyl group,~~

~~by a 4- to 7-membered cycloalkyleneimino, cycloalkyleneiminocarbonyl, cycloalkyleneiminosulphonyl, cycloalkyleneimino-C_{1-3}-alkyl, cycloalkyleneiminocarbonyl-C_{1-3}-alkyl or cycloalkyleneiminosulphonyl-C_{1-3}-alkyl group, wherein in each case the methylene group in the 4 position of a 6- or 7-membered cycloalkyleneimino group is optionally replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, -NH or -N(C_{1-3}-alkyl) group, or by a heteroaryl or heteroaryl-C_{1-3}-alkyl group~~ ;

R_4 denotes a hydrogen atom ~~,~~ or a C_{1-3}-alkyl group ~~or a prodrug group~~;

R_5 denotes a hydrogen atom or a C_{1-3}-alkyl group and

R_6 denotes a hydrogen, fluorine, chlorine, bromine or iodine atom,

a trifluoromethyl or heteroaryl group, a C_{1-3}-alkoxy group optionally substituted by 1 to 3 fluorine atoms, an amino-C_{1-3}-alkoxy, C_{1-3}-alkylamino-C_{2-3}-alkoxy or benzylamino-C_{2-3}-alkoxy group, a cycloalkyleneimino-C_{2-3}-alkoxy group with 4 to 7 ring members, a di-(C_{1-3}-alkyl)-amino-C_{2-3}-alkoxy or C_{1-3}-alkylmercapto group,

a nitro, cyano, carboxy, C_{1-3}-alkoxycarbonyl, aminocarbonyl, C_{1-3}-alkylaminocarbonyl, di-(C_{1-3}-alkyl)-aminocarbonyl, piperidinocarbonyl or tetrazolyl group,

a C_{1-3}-alkylcarbonylamino group optionally substituted at the nitrogen atom by a C_{1-3}-alkyl group,

an imidazolyl or piperazino group optionally substituted at the imino group by a C_{1-3}-alkyl group,

a C_{1-4}-alkyl group, which may be terminally substituted

by a hydroxy, C_{1-3}-alkoxy, carboxy, C_{1-3}-alkoxycarbonyl, amino, C_{1-4}-alkylamino, di-(C_{1-4}-alkyl)-amino, phenylamino, N-phenyl-C_{1-3}-alkylamino, phenyl-n-C_{1-3}-alkylamino, N-(C_{1-3}-alkyl)-phenyl-n-C_{1-3}-alkyl-amino or di-(phenyl-n-C_{1-3}-alkyl)-amino group,

by a 4- to 7-membered cycloalkyleneimino group wherein

a methylene group linked to the imino group is optionally replaced by a carbonyl or sulphonyl group or

one or two hydrogen atoms is optionally replaced by a C_{1-3}-alkyl group and/or

in each case the methylene group in the 4 position of a 6- or 7-membered cycloalkyleneimino group is optionally substituted by a carboxy, C_{1-3}-alkoxycarbonyl, aminocarbonyl, C_{1-3}-alkylaminocarbonyl, di-(C_{1-3}-alkyl)-aminocarbonyl, phenyl-n-C_{1-3}-alkylamino or N-(C_{1-3}-alkyl)-phenyl-n-C_{1-3}-alkylamino group or

is optionally replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, -NH or -N(C_{1-3}-alkyl) group,

by a 5- to 7-membered cycloalkenyleneimino group wherein the double bond is isolated from the nitrogen atom,

by a C_{4-7}-cycloalkylamino, N-(C_{1-3}-alkyl)-C_{4-7}-cycloalkylamino or C_{5-7}-cycloalkenylamino group wherein position 1 of the ring is not involved in

the double bond and wherein the nitrogen atom is optionally substituted by a C_{1-3}-alkyl group,

by a C_{1-3}-alkylcarbonylamino, N-(C_{1-3}-alkyl)-C_{1-3}-alkylcarbonylamino, aminocarbonyl, C_{1-3}-alkylaminocarbonyl or di-(C_{1-3}-alkyl)-aminocarbonyl group,

or R_6 denotes a group of formula

$$-N(R_a)-CO-(CH_2)_n-R_b \quad (II),$$

wherein

R_a denotes a C_{1-3}-alkyl group,

n one of the numbers 0, 1 or 2 and

R_b denotes an amino, C_{1-4}-alkylamino, phenylamino, N-(C_{1-4}-alkyl)-phenylamino, benzylamino, N-(C_{1-4}-alkyl)-benzylamino or di-(C_{1-4}-alkyl)-amino group or a 4- to 7-membered cycloalkyleneimino group, wherein in each case the methylene group in the 4 position of a 6- or 7-membered cycloalkyleneimino group is optionally replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, -NH or -N(C_{1-3}-alkyl) group,

a group of formula

$$-N(R_c)-(CH_2)_m-(CO)_o-R_d \quad (III),$$

wherein

R_c denotes a C_{1-3}-alkyl, C_{1-3}-alkylcarbonyl, arylcarbonyl, benzylcarbonyl, C_{1-3}-alkylsulphonyl, arylsulphonyl or benzylsulphonyl group,

m denotes one of the numbers 1, 2, 3 or 4,

o denotes one of the numbers 0 or 1 and

R_d has the meanings given for R_b hereinbefore or denotes a di-(C_{1-4}-alkyl)-amino-C_{1-3}-alkylamino group optionally substituted in the 1 position by a C_{1-3}-alkyl group,

or R_6 denotes an N-(C_{1-3}-alkyl)-C_{1-3}-alkylsulphonylamino group;

wherein any carboxy, amino or imino group present is optionally substituted by a group which can be cleaved in vivo,

or the physiologically acceptable salts and isomers thereof.

Claim 14. (Currently amended): The compound according to claim 13, wherein

X denotes an oxygen atom;

R_1 denotes a C_{1-3}-alkoxy, trifluoromethyl, di-(C_{1-3}-alkyl)-amino, pyrrolidino or pyrrolo group,

an amino or C_{1-3}-alkylamino group wherein an amino-hydrogen atom is optionally replaced by a C_{1-3}-alkylcarbonyl, phenyl-C_{1-3}-alkylcarbonyl, benzoyl, aminocarbonyl, C_{1-3}-alkylsulphonyl, phenylsulphonyl, carboxy-C_{1-3}-alkyl or C_{1-3}-alkyloxycarbonyl-C_{1-3}-alkyl group, or

a phenyl group optionally substituted by a C_{1-3}-alkyl group;

R_2 denotes a hydrogen atom or a C_{1-3}-alkoxy group or

R_1 and R_2 together denote a methylenedioxy group;

~~R_3 denotes a C_{1-3}-alkyl or phenyl group or a phenyl group substituted by a cyano, amino C_{1-3}-alkyl or N-(C_{1-3}-alkanoyl)-amino-C_{1-3}-alkyl group;~~

R_4 denotes a hydrogen atom;

R_5 denotes a hydrogen atom and

R_6 denotes a hydrogen, fluorine, chlorine, bromine or iodine atom,

a trifluoromethyl, 4-(C_{1-3}-alkyl)-piperazino, pyridinyl, imidazolyl, tetrazolyl, C_{1-3}-alkoxy or C_{1-3}-alkylmercapto group,

a nitro, cyano, carboxy or C_{1-3}-alkyloxycarbonyl group or a C_{1-3}-alkylcarbonylamino group optionally substituted at the nitrogen atom by a C_{1-3}-alkyl group,

a piperidinocarbonyl group or an aminocarbonyl group optionally substituted by one or two C_{1-3}-alkyl groups,

a C_{1-3}-alkyl group optionally terminally substituted

by an amino, C_{1-4}-alkylamino, di-(C_{1-4}-alkyl)-amino, phenylamino, N-phenyl-C_{1-3}-alkylamino, phenyl-n-C_{1-3}-alkylamino, N-(C_{1-3}-alkyl)-phenyl-n-C_{1-3}-alkylamino or di-(phenyl-n-C_{1-3}-alkyl)-amino group, by a pyrrolidino, piperidino, hexamethyleneimino, morpholino, thiomorpholino, 1-oxido-thiomorpholino or piperazino group wherein the piperidino group may additionally be substituted by one or two C_{1-3}-alkyl groups or by a carboxy, C_{1-3}-alkoxycarbonyl, aminocarbonyl, C_{1-3}-alkylaminocarbonyl- di-(C_{1-3}-alkyl)-aminocarbonyl or N-(C_{1-3}-alkyl)-phenyl-n-C_{1-3}-alkylamino group,

by a C_{5-7}-cycloalkylamino or C_{5-7}-cycloalkenylamino group wherein position 1 of the ring is not involved in the double bond,

by a C_{1-3}-alkylcarbonylamino, N-(C_{1-3}-alkyl)-C_{1-3}-alkylcarbonylamino, carboxy, C_{1-3}-alkoxycarbonyl, aminocarbonyl, C_{1-3}-alkylaminocarbonyl or di-(C_{1-3}-alkyl)-aminocarbonyl group,

a C_{1-3}-alkoxy group, which is terminally substituted by an amino, C_{1-3}-alkylamino or di-(C_{1-3}-alkyl)-amino group,

a group of formula

$$-N(R_a)-CO-(CH_2)_n-R_b \quad (II),$$

wherein

R_a denotes a C_{1-3}-alkyl group,
n denotes one of the numbers 0, 1 or 2 and
R_b denotes an amino, C_{1-4}-alkylamino or di-(C_{1-4}-alkyl)-amino group or a pyrrolidino, piperidino, hexamethyleneimino, morpholino, thiomorpholino, 1-oxido-thiomorpholino or piperazino group,

a group of formula

$$-N(R_c)-(CH_2)_m-(CO)_o-R_d \quad (III),$$

wherein

R_c denotes a C_{1-3}-alkyl, C_{1-3}-alkylcarbonyl or C_{1-3}-alkylsulphonyl group,
m denotes one of the numbers 1, 2, 3 or 4,
o denotes one of the numbers 0 or 1 and

R_d has the meanings given for R_b hereinbefore or denotes a di-(C_{1-4}-alkyl)-amino-C_{1-3}-alkylamino group optionally substituted in the 1 position by a C_{1-3}-alkyl group,

or R_6 denotes an N-(C_{1-3}-alkyl)-C_{1-3}-alkylsulphonylamino group.

Claim 15. (Currently amended): The compound according to claim 13, wherein

X denotes an oxygen atom;

R_1 denotes a methoxy, ethoxy, trifluoromethyl, phenyl, methylphenyl, dimethylamino, pyrrolidino or pyrrolo group,

an amino group which is optionally substituted by a methyl, carboxymethyl, methoxycarbonylmethyl, acetyl, phenylacetyl, benzoyl, methanesulphonyl, benzenesulphonyl or aminocarbonyl group;

R_2 denotes a hydrogen atom, a methoxy or ethoxy group or

R_1 and R_2 together denote a methylenedioxy group;

~~R_3 denotes an ethyl group or a phenyl group optionally substituted by a cyano, aminomethyl or N-acetyl-aminomethyl group;~~

R_4 denotes a hydrogen atom;

R_5 denotes a hydrogen atom and

R_6 denotes a hydrogen, fluorine, chlorine, bromine or iodine atom,

a methyl, trifluoromethyl, methoxy, ethoxy, methylmercapto, cyano, carboxy, methoxycarbonyl, ethoxycarbonyl, aminocarbonyl, dimethylaminocarbonyl, piperidinocarbonyl, nitro, 4-methyl-piperazino, imidazolyl, pyridinyl or tetrazolyl group,

an ethyloxy or n-propyloxy group terminally substituted by a dimethylamino group,

a methyl or ethyl group substituted by a carboxy, methoxycarbonyl, ethoxycarbonyl, aminocarbonyl or dimethylaminocarbonyl group,

a C_{1-3}-alkyl group, which is optionally terminally substituted

by an amino, C_{1-4}-alkylamino, cyclohexylamino, benzylamino or phenylamino group wherein a hydrogen atom of the amino-nitrogen atom is optionally replaced in each case by a C_{1-3}-alkyl, benzyl, acetyl or dimethylaminocarbonyl group,

by a piperidino group optionally substituted by one or two methyl groups,

by a piperidino group substituted by a carboxy, methoxycarbonyl, ethoxycarbonyl or dimethylaminocarbonyl group,

by a pyrrolidino, 3,4-dehydro-piperidino, hexamethyleneimino, morpholino, thiomorpholino, 1-oxo-thiomorpholino or piperazino group,

a C_{1-3}-alkylamino group wherein the hydrogen atom of the amino-nitrogen atom is replaced

by an ethyl or n-propyl group, each of which is terminally substituted by a dimethylamino group,

by a C_{2-3}-alkanoyl group which is optionally substituted in the 2 or 3 position by an amino, C_{1-3}-alkylamino, di-(C_{1-3}-alkyl)-amino, pyrrolidino, piperidino, morpholino or piperazino group,

by an aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, piperidinocarbonyl or methanesulphonyl group,

wherein the C_{1-3}-alkyl moiety of the C_{1-3}-alkylamino group is further optionally substituted

by an aminocarbonyl group,

by a C_{1-3}-alkylaminocarbonyl or di-(C_{1-3}-alkyl)-aminocarbonyl group wherein a C_{2-3}-alkyl moiety may additionally be terminally substituted by a dimethylamino group,

by a pyrrolidinocarbonyl, piperidinocarbonyl, morpholinocarbonyl or piperazinocarbonyl group,

and wherein the C_{2-3}-alkyl moiety of the abovementioned C_{1-3}-alkylamino group is also further optionally terminally substituted by an amino, C_{1-3}-alkylamino, di-(C_{1-3}-alkyl)-amino, pyrrolidino, piperidino, morpholino or piperazino group.

Claim 16. (Previously added): The compound according to claim 15, wherein
R_2 denotes a hydrogen atom.

Claim 17. (Previously added): The compound according to claim 14, wherein

R_1 and R_2, which are identical or different, each denote a C_{1-3}-alkoxy group.

Claim 18. (Currently amended): The compound according to claim 13, wherein

X denotes an oxygen atom;

R_1 denotes an amino, methoxy or ethoxy group;

R_2 denotes a hydrogen atom or in position 5 a methoxy or ethoxy group;

~~R_3 denotes a methyl, ethyl or phenyl group;~~

R_4 and R_5 each denote a hydrogen atom and

R_6 denotes a methyl or ethyl group substituted by a methylamino, ethylamino, piperidino or 4-(dimethylaminocarbonyl)-piperidino group, wherein the amino-hydrogen atom of the methylamino- and ethylamino group is replaced by a methyl or benzyl group, an N-dimethylaminomethylcarbonyl-N-methyl-amino group or an N-acetyl-N-(C_{2-3}-alkyl)-amino group wherein the C_{2-3}-alkyl moiety in each case is terminally substituted by a dimethylamino group.

Claim 19. (Currently amended): A compound chosen from

(a) 3-(Z)-{1-[4-(piperidin-1-yl-methyl)-anilino]-1-phenyl-methylidene}-5,6-dimethoxy-2-indolinone,

(b) 3-(Z)-(1-{4-[(N-benzyl-N-methyl-amino)-methyl]-anilino}-1-phenyl-methylidene)-5,6-dimethoxy-2-indolinone,

(c) 3-(Z)-{1-(4-(dimethylamino-methyl)-anilino]-1-phenyl-methylidene}-5,6-dimethoxy-2-indolinone,

(d) 3-(Z)-{1-[4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-anilino]-1-phenyl-methylidene}-5,6-dimethoxy-2-indolinone,

(e) 3-(Z)-(1-{4-[2-(4-dimethylcarboxamide-piperidin-1-yl)-ethyl]-anilino}-1-phenyl-methylidene)-5,6-dimethoxy-2-indolinone,

~~(f) 3-(Z)-{1-[4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-anilino]-1-ethyl-methylidene}-5,6-dimethoxy-2-indolinone and~~

(g) 6-amino-3-(Z)-{1-[4-(piperidin-1-yl-methyl)-anilino]-1-phenyl-methylidene}-2-indolinone,

(h) 3-(Z)-(1-{4-[N-acetyl-N-(2-dimethylamino-ethyl)-amino]-anilino}-1-phenyl-methylidene)-5,6-dimethoxy-2-indolinone and

(i) 3-(Z)-(1-{4-[N-acetyl-N-(3-dimethylamino-propyl)-amino]-anilino}-1-phenyl-methylidene)-5,6-dimethoxy-2-indolinone

or the physiologically acceptable salts and isomers thereof.

Claim 20. (Previously added): A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 13 and one or more inert carriers and/or diluents.

Claim 21-22. (Canceled)

Claim 23.(Previously added):A method of treating haemangiomas, metastasisation, rheumatoid arthritis, psoriasis, ocular neovascularisation or diabetic retinopathy,

comprising administering to a patient in need thereof a therapeutically effective amount of a compound according claim 13.

Claim 24. (Previously added): A process for preparing a compounds of the formula (I) according to claim 13
comprising:

a. reacting under suitable conditions a compound of the formula (IV)



(IV),

wherein
X and R_1 to R_3 are defined as in claim 13,
R_7 denotes a hydrogen atom, a protecting group for the nitrogen atom of the lactam group or a bond to a solid phase and

Z_1 denotes a halogen atom, a hydroxy, alkoxy or arylalkoxy group,

with an amine of the formula (V)



(V),

wherein

R_5 and R_6 are defined as in claim 1, and optionally cleaving a protecting group used for the nitrogen atom of the lactam group or a compound thus obtained is cleaved from a solid phase,

or

b. in order to prepare a compound of the formula (I)wherein R_1 denotes an amino group, reducing under suitable conditions a compound of the formula (VI)



(VI),

or

c. in order to prepare a compound of the formula (I) wherein R_1 and/or R_2 denotes one of the substituted sulphinyl or sulphonyl groups mentioned in claim 13,
oxidizing a compound of the formula (VII)



(VII),

wherein

R_3 to R_6 are defined as in claim 13 and

one of the groups R_1' and R_2' denotes one of the substituted mercapto or sulphinyl groups mentioned for R_1 and R_2 in claim 13 and the other assumes the meanings given for R_1 or R_2 in claim 13 with the exception of the mercapto or sulphinyl groups or both groups R_1' and R_2' denote one of the substituted mercapto or sulphinyl groups mentioned for R_1 and R_2 in claim 13,

and

subsequently, optionally hydrolizing a compound of general formula I thus obtained which contains an alkoxycarbonyl group into a corresponding carboxy compound or

converting a compound of the formula (I) thus obtained which contains an amino or alkylamino group by alkylation or reductive alkylation into a corresponding alkylamino, dialkylamino or pyrrolidino compound or

acylating a compound of the formula (I) thus obtained which contains an amino or alkylamino group into a corresponding acyl compound or

sulphonating a compound of the formula (I) thus obtained which contains an amino or alkylamino group into a corresponding sulphonyl compound or

condensing a compound of the formula (I) thus obtained which contains an amino group into a corresponding pyrrolo compound or

converting a compound of the formula (I) thus obtained which contains a carboxy group by esterification or amidation into a corresponding ester or aminocarbonyl compound or

reducing a compound of the formula (I) thus obtained which contains a cyano group into a corresponding aminomethyl compound or

converting a compound of the formula (I) thus obtained which contains an amino or alkylamino group by reaction with cyanic acid or a corresponding isocyanate into a corresponding ureido compound

and

optionally cleaving any protecting group used to protect reactive groups during the reactions or
optionally resolving into the stereoisomers thereof a compound of the formula (I) or
optionally converting a compound of the formula (I) thus obtained is into the physiologically acceptable salts thereof with an inorganic or organic acid or base
and subsequently isolating the product compound.

Claim 25. (New): A method of inhibiting tumour cell proliferation comprising contacting a cell with an effective amount of a compound according to claim 13.

Claim 26. (New): A method of inhibiting tumour cell proliferation comprising administering to a patient a therapeutically effective of a compound according to claim 13.

Claim 27. (New): A method of treating solid tumours, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according claim 13.

Claim 28. (New): A method of inhibiting endothelial cell proliferation comprising contacting a cell with an effective amount of a compound according to claim 13.

Claim 29. (New): A method of inhibiting endothelial cell proliferation comprising administering to a patient a therapeutically effective amount of a compound according to claim 13.